
  
    
      
        Background_NNP
        Aneuploidy_NNP is_VBZ a_DT common_JJ feature_NN of_IN cancer_NN ._. Genetic_JJ
        alterations_NNS such_JJ as_IN amplification_NN ,_, deletion_NN ,_, translocation_NN
        and_CC rearrangement_NN could_MD result_VB in_IN either_DT gain-of-function_JJ
        or_CC loss-of-function_JJ mutations_NNS in_IN genes_NNS that_WDT modulate_VBP
        aspects_NNS of_IN cell_NN proliferation_NN ,_, differentiation_NN ,_, motility_NN
        and_CC survival_NN ._. Whereas_IN cytogenetic_JJ profiling_VBG techniques_NNS ,_,
        such_JJ as_IN comparative_JJ genomic_JJ hybridization_NN (_( CGH_NNP )_) [_NN 1_CD ]_NN ,_, have_VBP
        been_VBN useful_JJ in_IN finding_VBG genetic_JJ abnormalities_NNS ,_, other_JJ
        experimental_JJ approaches_NNS are_VBP frequently_RB used_VBN to_TO identify_VB
        which_WDT specific_JJ gene_NN (_( s_VBZ )_) drive_NN selection_NN for_IN the_DT genetic_JJ
        aberration_NN and_CC contribute_VB most_JJS to_TO tumor_NN progression_NN ._. Common_JJ
        gene_NN identification_NN techniques_NNS include_VBP determining_VBG if_IN a_DT
        candidate_NN gene_NN contains_VBZ a_DT sequence_NN mutation_NN and_CC /_NN or_CC
        determining_VBG if_IN the_DT candidate_NN gene_NN or_CC gene_NN product_NN is_VBZ
        abnormally_RB expressed_VBN ._. As_IN mutation_NN analysis_NN and_CC protein_NN
        expression_NN studies_NNS are_VBP time-consuming_JJ ,_, increasingly_RB
        high-throughput_JJ gene-expression_JJ profiling_VBG is_VBZ being_VBG used_VBN to_TO
        identify_VB abnormally_RB expressed_VBD genes_NNS within_IN a_DT region_NN of_IN
        cytogenetic_JJ change_NN [_NN 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ]_NN ._.
        Recently_RB ,_, several_JJ groups_NNS have_VBP observed_VBN that_IN chromosomal_NN
        changes_NNS can_MD lead_VB to_TO regional_JJ biases_NNS in_IN gene-expression_JJ
        values_NNS both_DT in_IN yeast_NN (_( 
        Saccharomyces_NNP cerevisiae_NN )_) and_CC in_IN
        human_JJ tumors_NNS and_CC tumor-derived_JJ cell_NN lines_NNS [_NN 2_CD ,_, 3_CD ,_, 7_CD ,_, 8_CD ]_NN ._.
        These_DT studies_NNS suggest_VBP that_IN a_DT fraction_NN of_IN gene-expression_JJ
        values_NNS (_( 15_CD -_: 25_CD %_NN )_) are_VBP regulated_VBN in_IN concordance_NN with_IN gene_NN
        dosage_NN ._. A_DT computational_NN technique_NN termed_VBD comparative_JJ
        genomic_JJ microarray_NN analysis_NN (_( CGMA_NNP )_) has_VBZ previously_RB been_VBN used_VBN
        to_TO identify_VB regions_NNS of_IN allelic_JJ imbalance_NN indirectly_RB from_IN
        gene-expression_JJ profiles_NNS of_IN human_JJ tumors_NNS [_NN 8_CD ]_NN ._. CGMA_NNP
        predicts_VBZ chromosomal_NN amplifications_NNS and_CC deletions_NNS by_IN
        organizing_VBG gene-expression_JJ data_NNS by_IN genomic_JJ mapping_NN location_NN
        and_CC scanning_VBG for_IN regions_NNS that_WDT contain_VBP a_DT statistically_RB
        significant_JJ number_NN of_IN gene-expression_JJ values_NNS that_WDT change_NN in_IN
        the_DT same_JJ relative_JJ direction_NN ._. In_IN this_DT study_NN ,_, we_PRP apply_VBP CGMA_NNP
        analysis_NN to_TO a_DT large_JJ hepatocellular_NN carcinoma_NN microarray_NN
        dataset_NN to_TO demonstrate_VB its_PRP$ validity_NN as_IN an_DT alternative_NN to_TO
        CGH_NNP and_CC to_TO identify_VB candidate_NN genes_NNS in_IN regions_NNS of_IN frequent_JJ
        cytogenetic_JJ change_NN ._.
        Primary_JJ liver_NN cancer_NN in_IN adults_NNS is_VBZ the_DT sixth_JJ most_RBS common_JJ
        form_NN of_IN cancer_NN and_CC the_DT fourth_JJ leading_VBG cause_NN of_IN death_NN from_IN
        cancer_NN worldwide_NN [_NN 9_CD ,_, 10_CD ]_NN ._. Through_IN the_DT examination_NN of_IN
        hepatitis_NNP B_NNP virus_NN (_( HBV_NNP )_) -_: and_CC hepatitis_NNP C_NNP virus_NN
        (_( HCV_NNP )_) -_: induced_VBN tumors_NNS ,_, two_CD landmark_NN CGH_NNP studies_NNS have_VBP
        suggested_VBN that_IN a_DT subset_NN of_IN cytogenetic_JJ changes_NNS frequently_RB
        occurs_VBZ in_IN HCC_NNP [_NN 11_CD ,_, 12_CD ]_NN ._. These_DT include_VBP frequent_JJ gain_NN of_IN
        chromosomes_NNS 1_CD q_NN ,_, 6_CD p_NN ,_, 8_CD q_NN ,_, 17_CD q_NN and_CC 20_CD q_NN and_CC frequent_JJ loss_NN of_IN
        chromosomes_NNS 1_CD p_NN ,_, 4_CD q_NN ,_, 6_CD q_NN ,_, 8_CD p_NN ,_, 13_CD ,_, 16_CD and_CC 17_CD p_NN [_NN 11_CD ,_, 12_CD ]_NN ._. In_IN
        particular_JJ ,_, gain_NN of_IN chromosomes_NNS 1_CD q_NN and_CC 8_CD q_NN has_VBZ been_VBN
        associated_VBN with_IN the_DT early_JJ development_NN of_IN HCC_NNP [_NN 12_CD ]_NN ,_, whereas_IN
        loss_NN of_IN chromosome_NN 4_CD q_NN has_VBZ been_VBN linked_VBN to_TO increased_VBN
        aggressiveness_NN of_IN established_VBN tumors_NNS [_NN 11_CD ]_NN ._. To_TO determine_VB
        whether_IN gene-expression_JJ data_NNS could_MD be_VB used_VBN to_TO identify_VB
        cytogenetic_JJ changes_NNS accurately_RB ,_, we_PRP applied_VBD CGMA_NNP to_TO a_DT
        microarray_NN dataset_NN of_IN HCC_NNP tumors_NNS and_CC compared_VBD the_DT CGMA_NNP
        predictions_NNS to_TO existing_VBG CGH_NNP data_NNS ._. For_IN HCC_NNP ,_, CGMA_NNP was_VBD able_JJ to_TO
        predict_VB nearly_RB all_DT chromosomal_NN aberrations_NNS identified_VBN
        previously_RB by_IN CGH_NNP ._. In_IN addition_NN ,_, from_IN the_DT gene-expression_JJ
        data_NN we_PRP also_RB identified_VBD a_DT set_NN of_IN genes_NNS whose_WP$ expression_NN
        values_NNS change_VBP most_JJS within_IN the_DT regions_NNS of_IN cytogenetic_JJ
        change_NN ._. These_DT genes_NNS may_MD represent_VB candidate_NN genes_NNS whose_WP$
        expression_NN changes_NNS drive_VBP selection_NN for_IN chromosomal_NN gains_NNS or_CC
        losses_NNS ._.
      
      
        Results_NNS
        
          CGMA_NNP predictions_NNS of_IN cytogenetic_JJ changes_NNS
          Normalized_NNP ,_, log-transformed_JJ gene-expression_JJ data_NNS from_IN
          104_CD HCC_NNP gene-expression_JJ arrays_NNS [_NN 13_CD ]_NN were_VBD obtained_VBN from_IN
          the_DT Stanford_NNP Microarray_NNP Database_NNP [_NN 14_CD ]_NN ._. As_IN CGMA_NNP analysis_NN
          yields_NNS more_RBR intuitive_JJ predictions_NNS if_IN the_DT tumor_NN expression_NN
          data_NNS is_VBZ compared_VBN to_TO a_DT normal_JJ tissue_NN reference_NN ,_, the_DT
          original_JJ HCC_NNP gene-expression_JJ data_NNS was_VBD mathematically_RB
          transformed_VBN such_JJ that_IN the_DT pooled_VBN cell-line_JJ reference_NN was_VBD
          replaced_VBN by_IN a_DT normal_JJ tissue_NN reference_NN (_( [_NN 3_CD ]_NN ,_, see_VB
          Materials_NNPS and_CC methods_NNS )_) ._. Using_VBG this_DT transformation_NN ,_,
          gene-expression_JJ values_NNS from_IN the_DT tumor_NN sample_NN are_VBP compared_VBN
          to_TO corresponding_JJ values_NNS from_IN non-cancerous_JJ tissue_NN ._.
          Genomic_NNP regions_NNS that_WDT contain_VBP a_DT disproportionate_JJ number_NN of_IN
          genes_NNS that_WDT change_NN expression_NN in_IN the_DT same_JJ relative_JJ
          direction_NN (_( that_WDT is_VBZ ,_, show_NN a_DT gene-expression_JJ bias_NN )_) may_MD
          indicate_VB an_DT underlying_VBG chromosomal_NN gain_NN or_CC loss_NN (_( Figure_NN
          1_CD a_DT )_) [_NN 2_CD ,_, 3_CD ,_, 7_CD ,_, 8_CD ]_NN ._. Chromosomal_NNP regions_NNS that_WDT contained_VBD a_DT
          gene-expression_JJ bias_NN with_IN at_IN least_JJS 95_CD %_NN confidence_NN (_( a_DT sign_NN
          test_NN 
          z_SYM -_: statistic_NN of_IN at_IN least_JJS 1_CD ._. 96_CD ,_, see_VBP
          Materials_NNPS and_CC methods_NNS )_) were_VBD identified_VBN for_IN all_DT 104_CD HCC_NNP
          expression_NN profiles_NNS (_( Figure_NN 1_CD b_SYM )_) ._. In_IN addition_NN ,_, genomic_JJ
          regions_NNS that_WDT contained_VBD significant_JJ gene-expression_JJ biases_NNS
          in_IN at_IN least_JJS 35_CD %_NN of_IN non-replicate_JJ samples_NNS were_VBD identified_VBN
          (_( Figure_NN 1_CD c_SYM )_) ._. A_DT 35_CD %_NN threshold_NN was_VBD chosen_VBN because_IN in_IN
          previous_JJ CGMA_NNP profiling_VBG experiments_NNS this_DT threshold_NN
          yielded_VBD the_DT highest_JJS CGMA_NNP to_TO CGH_NNP agreement_NN (_( [_NN 8_CD ]_NN and_CC data_NNS
          not_RB shown_VBN )_) ._. CGMA_NNP predicted_VBD frequent_JJ gains_NNS for_IN chromosome_NN
          1_CD q_NN (_( gained_VBD in_IN 72_CD %_NN of_IN tumor_NN samples_NNS )_) ,_, 6_CD p_NN (_( 56_CD %_NN )_) ,_, 8_CD q_NN (_( 49_CD %_NN )_) ,_,
          17_CD q_NN (_( 46_CD %_NN )_) ,_, 20_CD q_NN (_( 46_CD %_NN )_) ,_, 5_CD q_NN (_( 42_CD %_NN )_) ,_, 19_CD P_NN (_( 37_CD %_NN )_) and_CC 12_CD q_NN (_( 35_CD %_NN )_) ._.
          Frequent_JJ chromosomal_NN losses_NNS were_VBD predicted_VBN for_IN chromosome_NN
          4_CD q_NN (_( lost_VBD in_IN 66_CD %_NN of_IN tumor_NN samples_NNS )_) ,_, 17_CD p_NN (_( 48_CD %_NN )_) ,_, 13_CD (_( 39_CD %_NN )_) ,_,
          16_CD (_( 37_CD %_NN )_) ,_, and_CC 8_CD p_NN (_( 35_CD %_NN )_) ._. To_TO determine_VB if_IN CGMA_NNP predictions_NNS
          were_VBD consistent_JJ with_IN other_JJ cytogenetic_JJ profiling_VBG studies_NNS ,_,
          the_DT CGMA_NNP data_NN were_VBD compared_VBN with_IN data_NNS from_IN two_CD of_IN the_DT
          largest_JJS CGH_NNP profiling_VBG studies_NNS (_( 67_CD and_CC 50_CD samples_NNS ,_,
          respectively_RB )_) using_VBG HCC_NNP tumors_NNS [_NN 11_CD ,_, 12_CD ]_NN ._. Of_IN the_DT 13_CD
          regions_NNS detected_VBN by_IN CGMA_NNP ,_, 10_CD (_( 77_CD %_NN )_) were_VBD also_RB implicated_VBN
          by_IN CGH_NNP (_( Figure_NN 1_CD c_SYM )_) ._. CGMA_NNP also_RB detected_VBD three_CD gained_VBD
          regions_NNS ,_, chromosomes_NNS 5_CD q_NN ,_, 12_CD q_NN and_CC 19_CD p_NN ,_, which_WDT were_VBD not_RB
          implicated_VBN in_IN the_DT CGH_NNP analysis_NN ._. CGMA_NNP failed_VBD to_TO discover_VB
          two_CD regions_NNS of_IN loss_NN detected_VBN by_IN CGH_NNP -_: chromosomes_NNS 1_CD p_NN and_CC
          6_CD q_NN ._. It_PRP is_VBZ noteworthy_JJ that_IN these_DT particular_JJ losses_NNS were_VBD
          not_RB identified_VBN in_IN both_DT CGH_NNP studies_NNS ._. These_DT data_NNS suggest_VBP
          that_IN CGMA_NNP predictions_NNS produce_VBP results_NNS very_RB similar_JJ to_TO
          traditional_JJ CGH_NNP profiling_VBG studies_NNS ._.
        
        
          Comparison_NNP to_TO previous_JJ HCC_NNP studies_NNS
          To_TO date_NN there_EX have_VBP been_VBN at_IN least_JJS 20_CD reports_NNS on_IN the_DT
          application_NN of_IN CGH_NNP to_TO HCC_NNP [_NN 11_CD ,_, 12_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ,_, 18_CD ,_, 19_CD ,_,
          20_CD ,_, 21_CD ,_, 22_CD ,_, 23_CD ,_, 24_CD ,_, 25_CD ,_, 26_CD ,_, 27_CD ,_, 28_CD ,_, 29_CD ,_, 30_CD ,_, 31_CD ,_, 32_CD ]_NN ._. To_TO
          determine_VB whether_IN the_DT differences_NNS between_IN the_DT CGMA_NNP
          predictions_NNS and_CC the_DT two_CD large_JJ CGH_NNP studies_NNS were_VBD similar_JJ to_TO
          the_DT experimental_JJ variation_NN observed_VBD between_IN different_JJ HCC_NNP
          CGH_NNP studies_NNS ,_, predictions_NNS produced_VBN by_IN CGMA_NNP were_VBD compared_VBN
          to_TO 13_CD different_JJ HCC_NNP CGH_NNP profiling_VBG studies_NNS (_( Figure_NN 2_LS )_) ._.
          CGMA_NNP produced_VBD 10_CD of_IN 13_CD (_( 77_CD %_NN )_) predictions_NNS that_WDT matched_VBD a_DT
          consensus_NN chromosomal_NN aberration_NN profile_NN ._. On_IN average_JJ ,_,
          each_DT CGH_NNP study_NN matched_VBD the_DT consensus_NN profile_NN in_IN 78_CD ±_NN 14_CD %_NN
          of_IN the_DT chromosomal_NN regions_NNS analyzed_VBD ._. Therefore_RB ,_, the_DT
          variation_NN in_IN CGMA_NNP results_NNS was_VBD similar_JJ to_TO the_DT variations_NNS
          between_IN independent_JJ CGH_NNP studies_NNS ._. These_DT results_NNS suggest_VBP
          that_IN CGMA_NNP profiling_VBG is_VBZ able_JJ to_TO predict_VB regions_NNS of_IN
          frequent_JJ chromosomal_NN imbalance_NN in_IN HCC_NNP as_RB well_RB as_IN CGH_NNP
          profiling_VBG ._. As_IN only_RB 4_CD of_IN the_DT 104_CD (_( 4_CD %_NN )_) samples_NNS analyzed_VBD
          scored_VBN positive_JJ for_IN HCV_NNP infection_NN ,_, we_PRP could_MD not_RB use_VB this_DT
          dataset_NN to_TO detect_VB significant_JJ cytogenetic_JJ differences_NNS
          between_IN HCV-infected_NNP verses_NNS HBV-infected_NNP individuals_NNS
          (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          CGMA_NNP predictions_NNS of_IN multifocal_NN tumors_NNS
          Included_VBN in_IN the_DT set_NN of_IN HCC_NNP gene-expression_JJ profiles_NNS
          were_VBD several_JJ cases_NNS in_IN which_WDT multiple_JJ tumor_NN nodules_NNS were_VBD
          removed_VBN from_IN the_DT same_JJ patient_NN ._. In_IN some_DT cases_VBZ the_DT nodules_NNS
          had_VBD related_VBN gene-expression_JJ profiles_NNS (_( patients_NNS HK_NNP 63_CD ,_,
          HK_NNP 64_CD ,_, HK_NNP 66_CD )_) whereas_IN in_IN other_JJ cases_NNS tumors_NNS from_IN the_DT same_JJ
          patient_NN had_VBD distinctive_JJ profiles_NNS (_( HK_NNP 65_CD ,_, HK_NNP 67_CD ,_, HK_NNP 85_CD )_) [_NN
          33_CD ]_NN ._. In_IN particular_JJ ,_, in_IN patient_NN HK_NNP 67_CD the_DT gene-expression_JJ
          profile_NN from_IN nodule_NN HK_NNP 67_CD ._. 1_LS was_VBD distinct_JJ from_IN the_DT
          expression_NN profiles_NNS from_IN nodules_NNS HK_NNP 67_CD ._. 2_LS and_CC HK_NNP 67_CD ._. 3_LS [_NN 33_CD ]_NN ._.
          Array_NNP CGH_NNP was_VBD used_VBN previously_RB to_TO determine_VB the_DT
          cytogenetic_JJ profiles_NNS of_IN the_DT tumor_NN nodules_NNS from_IN this_DT
          patient_NN [_NN 33_CD ]_NN ._. Array_NNP CGH_NNP identified_VBD common_JJ cytogenetic_JJ
          abnormalities_NNS in_IN patient_NN HK_NNP 67_CD 's_POS tumors_NNS ,_, including_VBG loss_NN of_IN
          chromosome_NN 15_CD q_NN ,_, an_DT unusual_JJ gain_NN of_IN chromosome_NN 19_CD q_NN ,_, and_CC
          loss_NN of_IN the_DT centromeric_JJ region_NN of_IN chromosome_NN 22_CD ._. However_RB ,_,
          additional_JJ cytogenetic_JJ changes_NNS were_VBD found_VBN in_IN tumors_NNS
          HK_NNP 67_CD ._. 2_LS and_CC HK_NNP 67_CD ._. 3_LS that_WDT were_VBD not_RB present_JJ in_IN HK_NNP 67_CD ._. 1_LS ._. The_DT
          cytogenetic_JJ profiling_VBG data_NNS coupled_VBN with_IN the_DT observation_NN
          that_IN HK_NNP 67_CD ._. 2_LS and_CC HK_NNP 67_CD ._. 3_LS were_VBD both_DT smaller_JJR in_IN size_NN and_CC had_VBD
          an_DT increased_VBN mitotic_JJ index_NN ,_, suggested_VBD that_IN HK_NNP 67_CD ._. 1_LS was_VBD the_DT
          primary_JJ tumor_NN and_CC HK_NNP 67_CD ._. 2_LS and_CC HK_NNP 67_CD ._. 3_LS were_VBD divergent_JJ HK_NNP 67_CD ._. 1_LS
          subclones_NNS ._. To_TO determine_VB whether_IN CGMA_NNP predictions_NNS agree_VBP
          with_IN this_DT monoclonal_NN origin_NN hypothesis_NNS ,_, CGMA_NNP profiles_NNS of_IN
          patient_NN HK_NNP 67_CD 's_POS tumor_NN nodules_NNS were_VBD isolated_VBN and_CC organized_VBN
          by_IN hierarchical_JJ clustering_VBG (_( Figure_NN 3_LS )_) ._. CGMA_NNP also_RB detected_VBD
          the_DT common_JJ chromosome_NN 19_CD q_NN gain_NN and_CC chromosome_NN 15_CD q_NN loss_NN in_IN
          the_DT HK_NNP 67_CD tumors_NNS ._. CGMA_NNP did_VBD not_RB identify_VB a_DT common_JJ loss_NN on_IN
          chromosome_NN 22_CD ,_, however_RB ,_, CGMA_NNP identified_VBD other_JJ genetic_JJ
          aberrations_NNS (_( +_NN 8_CD q_NN ,_, -_: 16_CD q_NN and_CC -_: 19_CD q_NN )_) consistently_RB found_VBD in_IN
          the_DT HK_NNP 67_CD tumors_NNS ._. CGMA_NNP also_RB identified_VBD additional_JJ
          aberrations_NNS (_( +_NN 2_CD q_NN ,_, +_NN 5_CD q_NN ,_, +_NN 12_CD q_NN )_) present_JJ in_IN H_NNP 67_CD ._. 2_LS and_CC H_NNP 67_CD ._. 3_LS
          that_WDT were_VBD not_RB found_VBN in_IN H_NNP 67_CD ._. 1_LS ._. Taken_VBN together_RB ,_, the_DT CGMA_NNP
          data_NN supports_VBZ the_DT hypothesis_NNS that_IN the_DT H_NNP 67_CD ._. 2_LS and_CC HK_NNP 67_CD ._. 3_LS
          tumor_NN nodules_NNS probably_RB arose_VBD from_IN HK_NNP 67_CD ._. 1_LS ,_, but_CC that_IN
          additional_JJ distinct_JJ cytogenetic_JJ events_NNS had_VBD occurred_VBN in_IN
          these_DT nodules_NNS during_IN tumor_NN progression_NN ._. In_IN contrast_NN ,_,
          tumor_NN nodules_NNS from_IN patient_NN HK_NNP 64_CD have_VBP very_RB similar_JJ
          gene-expression_JJ profiles_NNS and_CC very_RB similar_JJ cytogenetic_JJ
          profiles_NNS as_IN predicted_VBN by_IN CGMA_NNP ,_, suggesting_VBG that_IN these_DT
          tumors_NNS have_VBP common_JJ origins_NNS and_CC these_DT nodules_NNS have_VBP not_RB
          diverged_JJ significantly_RB from_IN the_DT original_JJ lineage_NN ._. In_IN
          addition_NN ,_, tumor_NN nodules_NNS from_IN patient_NN HK_NNP 85_CD showed_VBD
          distinctive_JJ expression_NN profiles_NNS and_CC distinct_JJ HBV_NNP
          integration_NN sites_NNS [_NN 33_CD ]_NN ._. Similarly_RB ,_, the_DT tumors_NNS from_IN
          patient_NN HK_NNP 85_CD also_RB show_NN distinct_JJ CGMA-predicted_NNP
          cytogenetic_JJ profiles_NNS ,_, reflecting_VBG the_DT independent_JJ
          transforming_VBG mechanism_NN (_( Figure_NN 3_LS )_) ._.
        
        
          Identification_NNP of_IN candidate_NN genes_NNS in_IN regions_NNS of_IN
          frequent_JJ cytogenetic_JJ change_NN
          Frequent_JJ cytogenetic_JJ abnormalities_NNS suggest_VBP that_IN
          tumor-modifying_JJ genes_NNS (_( oncogenes_NNS or_CC tumor_NN suppressors_NNS )_)
          may_MD be_VB driving_VBG selection_NN for_IN the_DT amplification_NN or_CC
          deletion_NN of_IN these_DT particular_JJ genetic_JJ regions_NNS [_NN 6_CD ,_, 11_CD ,_, 12_CD ,_,
          34_CD ,_, 35_CD ,_, 36_CD ]_NN ._. An_DT advantage_NN of_IN using_VBG CGMA_NNP profiling_VBG rather_RB
          than_IN traditional_JJ molecular_JJ genetic_JJ profiling_VBG is_VBZ that_DT
          access_NN to_TO gene-expression_JJ data_NNS is_VBZ inherent_JJ in_IN the_DT
          analysis_NN ._. CGMA_NNP allows_VBZ cytogenetic_JJ analysis_NN and_CC the_DT
          candidate_NN gene_NN approach_NN to_TO be_VB performed_VBN with_IN the_DT same_JJ
          dataset_NN ._. For_IN example_NN ,_, the_DT 
          c-myc_JJ oncogene_NN has_VBZ been_VBN postulated_JJ
          to_TO drive_VB selection_NN for_IN frequent_JJ chromosome_NN 8_CD q_NN
          amplification_NN ._. Though_IN 
          c-myc_JJ is_VBZ located_VBN on_IN a_DT region_NN that_IN
          both_DT CGMA_NNP and_CC CGH_NNP identify_VBP as_RB frequently_RB gained_VBD ,_, c-_NN 
          myc_NN 's_POS expression_NN is_VBZ increased_VBN more_JJR
          than_IN twofold_NN in_IN less_JJR than_IN 6_CD %_NN of_IN the_DT samples_NNS ._. In_IN fact_NN ,_, in_IN
          52_CD %_NN of_IN the_DT HCC_NNP tissue_NN samples_NNS ,_, c-_NN 
          myc_NN 's_POS expression_NN is_VBZ downregulated_JJ
          (_( Table_NNP 1_LS )_) ._. This_DT implies_VBZ that_WDT increased_VBD 
          c-myc_JJ expression_NN is_VBZ not_RB driving_VBG the_DT
          selection_NN for_IN the_DT amplification_NN of_IN chromosomal_NN region_NN 8_CD q_NN
          in_IN these_DT samples_NNS ._. In_IN the_DT small_JJ region_NN of_IN chromosome_NN 8_CD q_NN
          presented_VBN in_IN Table_NNP 1_CD ,_, two_CD other_JJ genes_NNS (_( for_IN squalene_NN
          monooxygenase_NN and_CC pro_FW 2000_CD )_) do_VBP show_VB increased_VBN expression_NN
          in_IN a_DT majority_NN of_IN HCC_NNP samples_NNS ._. Consistent_NNP with_IN previous_JJ
          reports_NNS examining_VBG gene-expression_JJ levels_NNS in_IN regions_NNS of_IN
          cytogenetic_JJ change_NN ,_, expression_NN levels_NNS for_IN a_DT large_JJ
          percentage_NN of_IN genes_NNS in_IN this_DT amplified_VBN region_NN remain_VB
          unchanged_JJ [_NN 3_CD ,_, 5_CD ,_, 8_CD ]_NN ._.
          The_DT set_NN of_IN genes_NNS that_WDT are_VBP consistently_RB misregulated_JJ in_IN
          regions_NNS of_IN frequent_JJ cytogenetic_JJ change_NN as_IN predicted_VBN by_IN
          CGMA_NNP are_VBP shown_VBN in_IN Table_NNP 2_CD ._. Platelet-derived_NNP growth_NN factor_NN
          receptor_NN alpha_NN is_VBZ consistently_RB downregulated_JJ in_IN a_DT region_NN
          of_IN frequent_JJ cytogenetic_JJ loss_NN and_CC this_DT suggests_VBZ that_DT loss_NN
          of_IN a_DT member_NN of_IN this_DT receptor_NN gene_NN family_NN is_VBZ important_JJ in_IN
          HCC_NNP progression_NN ._. It_PRP has_VBZ previously_RB been_VBN reported_VBN that_IN a_DT
          transcript_NN (_( 
          PRLTS_NNP )_) with_IN sequence_NN similarity_NN to_TO
          the_DT extracellular_NN domain_NN of_IN platelet-derived_JJ growth_NN
          factor_NN receptor_NN may_MD also_RB be_VB a_DT tumor_NN suppressor_NN for_IN HCC_NNP [_NN
          35_CD ]_NN ._. In_IN addition_NN ,_, consistently_RB increased_VBN expression_NN of_IN
          the_DT pituitary_JJ tumor_NN transforming_VBG gene_NN 1_CD oncogene_NN (_( 
          PTTG_NNP )_) is_VBZ observed_VBN in_IN these_DT samples_NNS
          (_( Table_NNP 2_LS )_) ._. 
          PTTG_NNP maps_NNS to_TO chromosome_NN 5_CD q_NN ,_, a_DT
          region_NN that_WDT was_VBD identified_VBN as_RB frequently_RB changed_VBN by_IN CGMA_NNP ,_,
          but_CC not_RB identified_VBN in_IN the_DT majority_NN of_IN CGH_NNP profiling_VBG
          studies_NNS ._. 
          PTTP_NNP overexpression_NN in_IN NIH_NNP 3_CD T_NN 3_CD
          cells_NNS induces_VBZ these_DT cells_NNS to_TO form_VB tumors_NNS when_WRB injected_VBN
          into_IN nude_JJ mice_NNS ._. Overexpression_NNP of_IN this_DT gene_NN may_MD result_VB
          from_IN frequent_JJ chromosomal_NN amplification_NN and_CC may_MD
          participate_VB in_IN HCC_NNP tumor_NN progression_NN ._.
        
        
          CGMA_NNP prediction_NN software_NN
          To_TO assist_VB in_IN identifying_VBG regions_NNS of_IN unidirectional_NN
          gene-expression_JJ bias_NN ,_, we_PRP have_VBP constructed_VBN a_DT web-based_JJ
          program_NN that_WDT processes_VBZ two-color_JJ gene-expression_JJ data_NNS and_CC
          identifies_VBZ genomic_JJ regions_NNS that_WDT contain_VBP gene-expression_JJ
          biases_NNS ._. The_DT input_NN for_IN this_DT program_NN is_VBZ a_DT simple_JJ
          tab-delimited_JJ gene-expression_JJ matrix_NN file_NN consisting_VBG of_IN
          columns_NNS for_IN the_DT probe_NN sequence_NN identifier_NN ,_, probe_NN name_NN ,_,
          and_CC gene-expression_JJ ratios_NNS ._. Because_IN different_JJ microarray_NN
          technologies_NNS use_VBP different_JJ identifiers_NNS to_TO describe_VB the_DT
          microarray_NN probe_NN ,_, the_DT program_NN translates_NNS probe_VBP sequence_NN
          identifiers_NNS (_( ids_NNS )_) such_JJ as_IN GenBank_NNP accession_NN numbers_NNS and_CC
          UniGene_NNP cluster_NN ids_NNS to_TO Ensembl_NNP transcript_NN ids_NNS using_VBG
          precompiled_JJ sequence_NN comparisons_NNS ._. After_IN data_NNS analysis_NN ,_, a_DT
          summary_NN table_NN is_VBZ displayed_VBN showing_VBG chromosomal_NN regions_NNS
          that_WDT show_NN significant_JJ (_( α_NN ≤_NN 0_CD ._. 05_CD )_) unidirectional_NN
          gene-expression_JJ bias_NN highlighted_VBN in_IN either_DT red_JJ or_CC green_JJ ,_,
          indicating_VBG either_CC increased_VBN or_CC decreased_VBN expression_NN
          biases_NNS ,_, respectively_RB ._. The_DT program_NN can_MD also_RB send_VB several_JJ
          output_NN files_NNS to_TO the_DT user_NN via_IN e-mail_JJ ._. These_DT files_NNS include_VBP
          a_DT summary_NN report_NN that_WDT contains_VBZ the_DT 
          z_SYM -_: statistic_NN for_IN each_DT chromosomal_NN
          region_NN (_( positive_JJ for_IN upregulated_JJ regions_NNS and_CC negative_JJ for_IN
          downregulated_JJ regions_NNS )_) and_CC a_DT list_NN of_IN genes_NNS located_VBN in_IN
          regions_NNS of_IN frequent_JJ cytogenetic_JJ change_NN ._. The_DT program_NN is_VBZ
          available_JJ at_IN [_NN 37_CD ]_NN ._.
        
      
      
        Discussion_NNP
        In_IN this_DT study_NN we_PRP have_VBP used_VBN gene-expression_JJ profiling_VBG
        data_NNS to_TO predict_VB cytogenetic_JJ changes_NNS that_WDT frequently_RB occur_VB
        in_IN HCC_NNP ._. Two_CD landmark_NN CGH_NNP analyses_NNS identified_VBD 12_CD different_JJ
        regions_NNS of_IN frequent_JJ imbalance_NN ._. However_RB ,_, one_CD study_NN found_VBD 8_CD
        regions_NNS and_CC the_DT other_JJ study_NN found_VBD 11_CD [_NN 11_CD ,_, 12_CD ]_NN ._. Five_CD of_IN
        these_DT 12_CD regions_NNS were_VBD not_RB found_VBN in_IN both_DT experiments_NNS ._. CGMA_NNP
        successfully_RB identified_VBD 10_CD of_IN 12_CD regions_NNS previously_RB
        distinguished_VBN by_IN CGH_NNP ._. CGMA_NNP also_RB detected_VBD three_CD regions_NNS that_WDT
        have_VBP not_RB been_VBN implicated_VBN by_IN these_DT CGH_NNP studies_NNS ._. On_IN average_JJ
        however_RB ,_, 22_CD %_NN of_IN genomic_JJ regions_NNS indentified_JJ in_IN a_DT particular_JJ
        HCC_NNP CGH_NNP study_NN are_VBP not_RB constantly_RB identified_VBN in_IN other_JJ
        studies_NNS ._. Therefore_RB ,_, the_DT three_CD inconsistent_JJ CGMA_NNP predictions_NNS
        (_( 3_CD of_IN 13_CD ;_: 23_CD %_NN )_) are_VBP comparable_JJ to_TO the_DT inconsistencies_NNS
        between_IN independent_JJ CGH_NNP studies_NNS for_IN HCC_NNP ._.
        Three_CD additional_JJ regions_NNS were_VBD identified_VBN by_IN CGMA_NNP that_WDT
        were_VBD not_RB identified_VBN by_IN CGH_NNP ._. While_IN these_DT CGMA-predicted_NNP
        regions_NNS were_VBD near_IN the_DT 35_CD %_NN cutoff_NN for_IN detection_NN ,_, they_PRP could_MD
        represent_VB other_JJ regions_NNS of_IN allelic_JJ imbalance_NN yet_RB to_TO be_VB
        detected_VBN by_IN CGH_NNP ._. It_PRP is_VBZ also_RB possible_JJ that_IN biological_JJ
        mechanisms_NNS other_JJ than_IN cytogenetic_JJ change_NN could_MD influence_VB
        expression_NN in_IN large_JJ genomic_JJ regions_NNS and_CC produce_VB regional_JJ
        gene-expression_JJ biases_NNS ._. Additional_JJ molecular_JJ genetic_JJ work_NN
        will_MD be_VB required_VBN to_TO resolve_VB these_DT differences_NNS ._.
        If_IN CGH_NNP data_NNS are_VBP not_RB available_JJ for_IN a_DT particular_JJ cancer_NN
        type_NN ,_, but_CC gene-expression_JJ profiling_VBG data_NNS are_VBP ,_, then_RB CGMA_NNP
        could_MD allow_VB rapid_JJ prediction_NN of_IN the_DT cytogenetic_JJ
        abnormalities_NNS that_WDT frequently_RB occur_VB within_IN that_DT cancer_NN
        type_NN ._. Moreover_RB ,_, in_IN instances_NNS where_WRB gene-expression_JJ
        profiling_VBG reveals_VBZ previously_RB unrecognized_JJ cancer_NN subtypes_NNS ,_,
        CGMA_NNP could_MD determine_VB whether_IN cytogenetic_JJ differences_NNS are_VBP
        responsible_JJ for_IN these_DT different_JJ subtypes_NNS ._. In_IN cancer_NN types_NNS
        where_WRB traditional_JJ cytogenetic_JJ profiling_VBG has_VBZ already_RB been_VBN
        carried_VBN out_IN ,_, CGMA_NNP predictions_NNS could_MD serve_VB to_TO confirm_VB
        existing_VBG cytogenetic_JJ profiling_VBG data_NNS and_CC be_VB used_VBN further_JJ to_TO
        examine_VB candidate_NN genes_NNS whose_WP$ expression_NN changes_NNS most_JJS
        within_IN a_DT region_NN of_IN frequent_JJ cytogenetic_JJ change_NN ._. In_IN this_DT way_NN
        CGMA_NNP can_MD be_VB combined_VBN with_IN the_DT candidate_NN gene_NN approach_NN to_TO
        identify_VB genes_NNS that_WDT are_VBP directly_RB involved_VBN in_IN tumor_NN
        progression_NN ._.
      
      
        Conclusions_NNP
        CGMA_NNP can_MD be_VB used_VBN to_TO indicate_VB chromosomal_NN imbalances_NNS by_IN
        detecting_VBG chromosomal_NN regions_NNS that_WDT contain_VBP a_DT
        disproportionate_JJ number_NN of_IN gene-expression_JJ values_NNS that_WDT
        change_NN in_IN the_DT same_JJ relative_JJ direction_NN ._. This_DT analysis_NN
        provides_VBZ good_JJ evidence_NN that_IN CGMA_NNP is_VBZ a_DT practical_JJ alternative_NN
        to_TO CGH_NNP cytogenetic_JJ profiling_VBG when_WRB gene-expression_JJ profiling_VBG
        data_NNS is_VBZ available_JJ ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Normalization_NNP and_CC filtering_VBG
          Normalized_NNP ,_, log-transformed_JJ gene-expression_JJ data_NNS for_IN
          104_CD HCC_NNP samples_NNS and_CC 76_CD corresponding_JJ non-cancerous_JJ liver_NN
          gene-expression_JJ profiles_NNS [_NN 13_CD ]_NN were_VBD obtained_VBN from_IN the_DT
          Stanford_NNP Microarray_NNP Database_NNP [_NN 14_CD ]_NN ._. Genes_NNP that_WDT were_VBD
          present_JJ in_IN at_IN least_JJS 75_CD %_NN of_IN samples_NNS (_( 10_CD ,_, 037_CD genes_NNS )_) were_VBD
          used_VBN for_IN further_JJ analysis_NN ._. In_IN this_DT study_NN ,_, both_DT the_DT tumor_NN
          samples_NNS and_CC normal_JJ tissue_NN samples_NNS were_VBD compared_VBN to_TO a_DT
          pooled_VBN cell-line_JJ reference_NN [_NN 3_CD ]_NN ._. To_TO allow_VB comparison_NN of_IN
          tumor_NN gene-expression_JJ values_NNS to_TO gene-expression_JJ values_NNS
          from_IN surrounding_VBG non-cancerous_JJ tissue_NN ,_, new_JJ gene_NN
          expression_NN ratios_NNS ,_, tumor_NN verse_NN normal_JJ (_( T_NN /_NN N_NNP )_) ,_, were_VBD
          estimated_VBN ._. To_TO create_VB the_DT new_JJ ratios_NNS ,_, log-transformed_JJ
          non-cancerous_JJ tissue_NN ratios_NNS (_( N_NNP /_NN U_NNP )_) were_VBD subtracted_VBN from_IN
          the_DT log-transformed_JJ HCC_NNP tissue_NN ratios_NNS (_( T_NN /_NN U_NNP )_) for_IN each_DT gene_NN
          such_JJ that_WDT log_VBP 
          2_CD (_( T_NN /_NN N_NNP )_) =_SYM log_VB 
          2_CD (_( T_NN /_NN U_NNP )_) -_: log_VB 
          2_CD (_( N_NNP /_NN U_NNP )_) ._. If_IN an_DT HCC_NNP sample_NN did_VBD not_RB have_VB
          a_DT corresponding_JJ non-cancerous_JJ sample_NN ,_, the_DT global_JJ mean_NN of_IN
          the_DT non-cancerous_JJ tissue_NN gene-expression_JJ ratios_NNS were_VBD
          used_VBN ._.
        
        
          CGMA_NNP analysis_NN
          To_TO identify_VB regional_JJ gene-expression_JJ biases_NNS ,_,
          gene-expression_JJ values_NNS that_WDT map_NN within_IN a_DT given_VBN
          chromosomal_NN arm_NN were_VBD collected_VBN and_CC a_DT sign_NN test_NN for_IN a_DT
          one-sample_JJ mean_NN /_NN median_NN was_VBD used_VBN to_TO determine_VB whether_IN a_DT
          significant_JJ upward_RB or_CC downward_JJ bias_NN was_VBD present_JJ in_IN the_DT
          expression_NN values_NNS ._. An_DT exception_NN was_VBD made_VBN for_IN chromosomes_NNS
          13_CD -_: 16_CD ,_, 21_CD and_CC 22_CD ._. These_DT chromosomes_NNS are_VBP more_RBR telocentric_JJ
          and_CC therefore_RB only_RB their_PRP$ q-arms_JJ were_VBD tested_VBN for_IN
          expression_NN biases_NNS ._. Sequence_NNP comparisons_NNS were_VBD used_VBN to_TO map_VB
          microarray_NN probe_NN sequences_NNS (_( the_DT sequences_NNS that_WDT are_VBP placed_VBN
          on_IN the_DT microarray_NN )_) to_TO predicted_VBD Ensembl_NNP transcripts_NNS
          (_( Ensembl_NNP version_NN 6_CD ._. 28_CD )_) [_NN 8_CD ]_NN ._. Included_VBN in_IN the_DT Ensembl_NNP
          transcript_NN annotations_NNS are_VBP chromosomal_NN mapping_VBG locations_NNS
          at_IN base-pair_JJ resolution_NN ._. Redundancy_NNP introduced_VBN by_IN
          replicate_VB probes_NNS on_IN the_DT array_NN and_CC /_NN or_CC multiple_JJ probes_NNS
          mapping_NN to_TO the_DT same_JJ gene_NN were_VBD eliminated_VBN by_IN averaging_VBG
          expression_NN values_NNS that_WDT map_NN to_TO identical_JJ transcripts_NNS ._. Of_IN
          the_DT filtered_VBN set_NN of_IN 10_CD ,_, 037_CD genes_NNS ,_, 6_CD ,_, 274_CD genes_NNS (_( 63_CD %_NN )_) were_VBD
          unique_JJ and_CC had_VBD associated_VBN genomic_JJ mapping_NN
          information_NN ._.
          A_DT sign_NN test_NN for_IN the_DT one-sample_JJ mean_NN /_NN median_NN was_VBD used_VBN to_TO
          determine_VB whether_IN a_DT significant_JJ number_NN of_IN genes_NNS that_WDT map_NN
          to_TO a_DT given_VBN chromosomal_NN region_NN change_NN in_IN a_DT unidirectional_NN
          manner_NN ._. The_DT algorithm_NN scores_NNS a_DT gene_NN as_RB up_RB (_( +_NN )_) or_CC down_RB (_( -_: )_)
          regulated_VBN if_IN the_DT magnitude_NN of_IN the_DT expression_NN value_NN change_NN
          is_VBZ at_IN least_JJS 1_CD ._. 8_CD -_: fold_VB ._. The_DT sign_NN test_NN computes_VBZ the_DT
          probability_NN ,_, in_IN the_DT form_NN of_IN a_DT 
          z_SYM -_: statistic_NN ,_, of_IN finding_VBG 
          x_SYM upregulated_JJ genes_NNS out_IN of_IN 
          n_NN genes_NNS that_WDT change_NN in_IN a_DT given_VBN
          genomic_JJ region_NN ._. For_IN simplicity_NN ,_, the_DT 
          z_SYM -_: statistic_NN is_VBZ computed_JJ using_VBG the_DT
          normal_JJ approximation_NN to_TO the_DT binomial_NN distribution_NN such_JJ
          that_IN 
          z_SYM =_SYM (_( 2_CD 
          x_SYM -_: 
          n_NN )_) /_NN sqrt_NN (_( 
          n_NN )_) ._. Genomic_NNP regions_NNS that_WDT contained_VBD
          less_JJR than_IN 15_CD changed_VBN gene-expression_JJ values_NNS were_VBD excluded_VBN
          from_IN further_JJ analysis_NN ._. On_IN average_JJ ,_, 160_CD gene-expression_JJ
          values_NNS were_VBD located_VBN to_TO each_DT genomic_JJ region_NN ._. The_DT sign_NN test_NN
          
          z_SYM -_: statistic_NN can_MD be_VB converted_VBN to_TO a_DT
          significance_NN value_NN (_( α_NN )_) based_VBN on_IN the_DT two-tailed_JJ 
          z_SYM -_: statistic_NN (_( 
          z_SYM 
          α_NN /_NN 2_LS )_) critical_JJ values_NNS ._. For_IN example_NN ,_, if_IN
          
          z_SYM =_SYM 1_CD ._. 96_CD ,_, then_RB α_NN =_SYM 0_CD ._. 05_CD ;_: if_IN 
          z_SYM =_SYM 2_CD ._. 58_CD then_RB α_NN =_SYM 0_CD ._. 01_CD ,_, and_CC so_RB
          on_IN ._.
        
      
    
  
